REX 8756
Alternative Names: REX-8756; SAR-448755Latest Information Update: 22 Dec 2025
At a glance
- Originator Recludix Pharma
- Class Anti-inflammatories; Antiasthmatics; Skin disorder therapies; Small molecules
- Mechanism of Action STAT6 transcription factor inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Asthma; Atopic dermatitis; Chronic obstructive pulmonary disease
Most Recent Events
- 16 Dec 2025 US FDA approves IND application for REX 8756 for phase-I trial in Asthma, Chronic obstructive pulmonary disease (COPD) and Atopic dermatitis (In volunteers) (PO)
- 16 Dec 2025 Recludix Pharma plans phase-I trial for Asthma, Chronic obstructive pulmonary disease (COPD) and Atopic dermatitis (In volunteers) (PO)
- 14 Jun 2025 Recludix Pharma and Sanofi agree to co-develop STAT6 transcription factor inhibitors for multiple immunological and inflammatory indications